Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cloratadd D is a fixed-dose combination drug product containing loratadine and pseudoephedrine sulfate, developed by EMS S/A and evaluated in clinical trials by Azidus Brasil. Loratadine is a long-acting, non-sedating tricyclic antihistamine that selectively antagonizes peripheral histamine H1 receptors. Pseudoephedrine sulfate is an orally active sympathomimetic amine that exerts a decongestant effect on the nasal mucosa by acting as an agonist at alpha-adrenergic receptors, leading to vasoconstriction. The combination is primarily indicated for the relief of symptoms associated with allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and lacrimation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cloratadd D.